AAAAAA

   
Results: 1-11 |
Results: 11
Morbidity and mortality in patients waiting for coronary artery bypass surgery
Authors: Koomen, EH Hutten, BA Kelder, JC Redekop, WK Tijssen, JGP Kingma, JH
Citation: Eh. Koomen et al., Morbidity and mortality in patients waiting for coronary artery bypass surgery, EUR J CAR-T, 19(3), 2001, pp. 260-265
Oral anticoagulant therapy during and after coronary angioplasty - The intensity and duration of anticoagulation are essential to reduce thrombotic complications
Authors: ten Berg, JM Hutten, BA Kelder, JC Verheugt, FWA Plokker, HWT
Citation: Jm. Ten Berg et al., Oral anticoagulant therapy during and after coronary angioplasty - The intensity and duration of anticoagulation are essential to reduce thrombotic complications, CIRCULATION, 103(16), 2001, pp. 2042-2047
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
Authors: Hutten, BA Prins, MH Gent, M Ginsberg, J Tijssen, JGP Buller, HR
Citation: Ba. Hutten et al., Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis, J CL ONCOL, 18(17), 2000, pp. 3078-3083
Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis
Authors: van den Belt, AGM Hutten, BA Prins, MH Bossuy, PMM
Citation: Agm. Van Den Belt et al., Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis, THROMB HAEM, 84(5), 2000, pp. 758-763
Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: Cancer as a risk factor
Authors: Otten, HMMB Prins, MH Smorenburg, SM Hutten, BA
Citation: Hmmb. Otten et al., Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: Cancer as a risk factor, HAEMOSTASIS, 30, 2000, pp. 72-76
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison
Authors: Cromheecke, ME Levi, M Colly, LP de Mol, BJM Prins, MH Hutten, BA Mak, R Keyzers, KCJ Buller, HR
Citation: Me. Cromheecke et al., Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison, LANCET, 356(9224), 2000, pp. 97-102
Safety of treatment with oral anticoagulants in the elderly - A systematicreview
Authors: Hutten, BA Lensing, AWA Kraaijenhagen, RA Prins, MH
Citation: Ba. Hutten et al., Safety of treatment with oral anticoagulants in the elderly - A systematicreview, DRUG AGING, 14(4), 1999, pp. 303-312
Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists
Authors: Hutten, BA Prins, MH Redekop, WK Tijssen, JGP Heisterkamp, SH Buller, HR
Citation: Ba. Hutten et al., Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists, THROMB HAEM, 82(4), 1999, pp. 1260-1263
Long-term treatment of venous thromboembolic disease
Authors: Prins, MH Hutten, BA Koopman, MMW Buller, HR
Citation: Mh. Prins et al., Long-term treatment of venous thromboembolic disease, THROMB HAEM, 82(2), 1999, pp. 892-898
Should patients with venous thromboembolism and cancer be treated differently?
Authors: Smorenburg, SM Hutten, BA Prins, MH
Citation: Sm. Smorenburg et al., Should patients with venous thromboembolism and cancer be treated differently?, HAEMOSTASIS, 29, 1999, pp. 91-97
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
Authors: Kuijer, PMM Hutten, BA Prins, MH Buller, HR
Citation: Pmm. Kuijer et al., Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, ARCH IN MED, 159(5), 1999, pp. 457-460
Risultati: 1-11 |